JAKARTA. PT Itama Ranoraya Tbk (IRRA), a wholesale issuer for medical devices, will add a number of new business lines to strengthen sales performance.

According to idnfinancials.com data, a number of new business lines that will be carried out by IRRA include wholesale trading of fertilizers and agrochemical products, pharmaceutical drugs for humans, laboratory equipment and pharmaceuticals for veterinary medicine, as well as radioactive substances and ionizing radiation generators.

IRRA will seek approval from shareholders at a meeting scheduled for June 22, 2023.

Currently, IRRA has completed a feasibility analysis regarding the addition of a number of these new business lines. Based on an analysis from the appointed Public Appraisal Service Office (KJPP), the company was declared eligible to add a number of new business lines.

"Through the addition of the KBLI (Indonesian Business Field Standard Classification), the company hopes to be able to optimize all potential and opportunities and improve the company's performance and profitability in the future," wrote IRRA Management, in an information disclosure on the Indonesia Stock Exchange (IDX).

According to idnfinancials.com data, IRRA posted net sales of IDR 753.57 billion in the 2022 fiscal year. Sales in this period fell 42.89% from actual sales in 2021, which reached IDR 1.31 trillion. (KR/LM)